Oncternal Therapeutics, Inc. (ONCT)

Market Cap	1.56M
Revenue (ttm)	2.16M +227.9%
Net Income	-34.58M
EPS	-11.69
Shares Out	2.96M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	644,135
Open	0.7000
Previous Close	0.6940
Day's Range	0.5270 - 0.7000
52-Week Range	0.5270 - 13.2000
Beta	1.20
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 6, 2024

About ONCT

Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company’s clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial. It is also developing ONCT-808, a chimeric antigen receptor T-cells (C...

• Industry: Biotechnology
• Sector: Healthcare
• CEO: James Breitmeyer
• Employees: 30
• Stock Exchange: NASDAQ
• Ticker Symbol: ONCT
• Website: https://www.oncternal.com

Financial Performance

In 2023, Oncternal Therapeutics's revenue was $785,000, a decrease of -47.32% compared to the previous year's $1.49 million. Losses were -$39.48 million, -10.62% less than in 2022.

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Jan 1, 2000

Data Sources Report a data error